Etranacogene dezaparvovec for hemophilia B gene therapy.

Ther Adv Rare Dis · 2021 · PMC10032433 · PMID 37181105

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

40 The mean FIX activity was 32.7 (<2–90.4) in those with preexisting NAb compared with 41.3 IU/dL (range = 9.4–97.1) in those without preexisting NAb. Statistical analysis showed a trend to lower FIX activity in the preexisting NAb group ( R 2 = 0.078).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.